Pharmacokinetics of etodolac in patients with stable juvenile rheumatoid arthritis

Analytical Procedure for Determination of Cyclooxygenase-2 Inhibitors in Biological Fluids by High Performance Liquid Chromatography: A Review

“…Etodolac or 1,8-diethyl-1,3,4,9-tetrahydropyano [3,4-b] indole-1-acetic acid, is a non-steroidal anti-inflammatory drug which has been shown to be effective in the treatment of rheumatoid and osteoarthritis and a selective COX-2 inhibitors in a wide range of clinical relevant assays in direct comparisons with other NSAIDs [96,97]. Its chemical structure is shown in Fig.…”

Role of the selective cyclo-oxygenase-2 (COX-2) inhibitors in children

“…7 The study involved 11 patients aged 8-14 years. Clearance values for paediatric and adolescent patients were comparable to those of adults and were independent of age.…”

An ionic liquid-in-water microemulsion as a potential carrier for topical delivery of poorly water soluble drug: Development, ex-vivo and in-vivo evaluation

“…Recently, we have reported an IL based ME comprising 1-Butyl-3-methylimidazolium bromide (BMIMBr ) as IL and isopropyl myristate (IPM) stabilized by Tween 80 and Span 20 for dermal delivery of 5-Fluorouracil, a poorly water soluble anticancer drug (Goindi et al, 2014). Etodolac (ETO) is a poorly water soluble NSAID used to relieve inflammation, swelling, stiffness, and pain associated with rheumatoid arthritis, osteoarthritis (Simon et al, 2004) and juvenile rheumatoid arthritis (Boni et al, 1999). It shows poor oral bioavailability, gastrointestinal and cardiovascular side effects following oral administration (Barakat, 2006).…”